Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600770137> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W2600770137 abstract "4086 Background: Sunitinib is an receptor tyrosine kinase (RTK) inhibitor of VEGFR1-3, PDGFR-α-β, and other RTK. After we established Sunitinib (Sun) alone associated with limited response rate (RR) and good tolerability in refractory advanced esophagogastric cancer patients (Moehler et al. EUR J Cancer. 2011, 47: 1511), this double-blinded placebo-controlled phase II evaluated safety and efficacy of SUN as add-on in second-line or third-line FOLFIRI (ClinicalTrials.gov NCT01020630). Methods: Patients with failure of any prior docetaxel and/or platinum-based chemotherapy were randomized to receive 6-week cycles including FOLFIRI two weekly and SUN (25 mg) versus (vs) placebo (PLA) daily for 4 consecutive weeks followed by a 2-week rest. Primary endpoint was progression-free survival (PFS). Results: 91 randomized patients (ITT) had similar characteristics in both groups (SUN/PLA 45/46). Both groups had 2.7 treatment cycles. Objective RR was 20/29%, and tumor control rate was 58/56 % for SUN/PLA, respectively. Median PFS was similar for SUN vs. PLA with 3.6 vs. 3.3 months, respectively (HR 1.11; 95%CI 0.70-1.74, P = 0.66). Median overall survival (OS) was longer for SUN vs. PLA with 10.5 vs. 9.0 months, in ITT (HR 0.816; 95%CI 0.50 - 1.34, P = 0.42, one-sided 0.21) and in the per protocol population (HR 0.71; 95%CI 0.41 - 1.24, P = 0.23) respectively. No unexpected higher toxicities, SAE or SUSAR occurred with SUN. For SUN/PLA, all grade AEs (%) possibly related to study drug were nausea 49/47%, fatigue 36/29%, vomiting 27/29%, diarrhoea 36/38%, neutropenia 62/22%, stomatitis 27/20%, and palmar-plantar erythrodysaesthesia 13/3%, and Grade 3+ AEs (%) were neutropenia 56/20%, diarrhoea 2/13%, nausea 7/7%, fatigue 0/9% and pain 0/9%, respectively. Performed quality of life outcomes were mostly in favor of Sunitinib. Conclusions: In our phase II trial, Sunitinib added to FOLFIRI increased hematotoxicity and did not improve response rates or PFS in chemotherapy-resistant GC patients. Since the regimen was safe and patients had a trend to better OS, biomarker analyses will be performed to identify subgroups that benefit from add-on Sunitinib. Clinical trial information: NCT01020630." @default.
- W2600770137 created "2017-04-07" @default.
- W2600770137 creator A5009529288 @default.
- W2600770137 creator A5028867235 @default.
- W2600770137 creator A5030705786 @default.
- W2600770137 creator A5035577287 @default.
- W2600770137 creator A5038131926 @default.
- W2600770137 creator A5045251394 @default.
- W2600770137 creator A5049551730 @default.
- W2600770137 creator A5050929435 @default.
- W2600770137 creator A5053589015 @default.
- W2600770137 creator A5071888326 @default.
- W2600770137 creator A5072163653 @default.
- W2600770137 creator A5073726610 @default.
- W2600770137 creator A5078248078 @default.
- W2600770137 creator A5083168604 @default.
- W2600770137 creator A5089874947 @default.
- W2600770137 creator A5091422927 @default.
- W2600770137 date "2013-05-20" @default.
- W2600770137 modified "2023-10-01" @default.
- W2600770137 title "FOLFIRI plus sunitinib versus FOLFIRI alone in advanced chemorefractory esophagogastric cancer patients: A randomized placebo-controlled multicentric AIO phase II trial." @default.
- W2600770137 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.4086" @default.
- W2600770137 hasPublicationYear "2013" @default.
- W2600770137 type Work @default.
- W2600770137 sameAs 2600770137 @default.
- W2600770137 citedByCount "7" @default.
- W2600770137 countsByYear W26007701372014 @default.
- W2600770137 countsByYear W26007701372015 @default.
- W2600770137 countsByYear W26007701372016 @default.
- W2600770137 countsByYear W26007701372017 @default.
- W2600770137 crossrefType "journal-article" @default.
- W2600770137 hasAuthorship W2600770137A5009529288 @default.
- W2600770137 hasAuthorship W2600770137A5028867235 @default.
- W2600770137 hasAuthorship W2600770137A5030705786 @default.
- W2600770137 hasAuthorship W2600770137A5035577287 @default.
- W2600770137 hasAuthorship W2600770137A5038131926 @default.
- W2600770137 hasAuthorship W2600770137A5045251394 @default.
- W2600770137 hasAuthorship W2600770137A5049551730 @default.
- W2600770137 hasAuthorship W2600770137A5050929435 @default.
- W2600770137 hasAuthorship W2600770137A5053589015 @default.
- W2600770137 hasAuthorship W2600770137A5071888326 @default.
- W2600770137 hasAuthorship W2600770137A5072163653 @default.
- W2600770137 hasAuthorship W2600770137A5073726610 @default.
- W2600770137 hasAuthorship W2600770137A5078248078 @default.
- W2600770137 hasAuthorship W2600770137A5083168604 @default.
- W2600770137 hasAuthorship W2600770137A5089874947 @default.
- W2600770137 hasAuthorship W2600770137A5091422927 @default.
- W2600770137 hasConcept C121608353 @default.
- W2600770137 hasConcept C126322002 @default.
- W2600770137 hasConcept C142724271 @default.
- W2600770137 hasConcept C143998085 @default.
- W2600770137 hasConcept C168563851 @default.
- W2600770137 hasConcept C204787440 @default.
- W2600770137 hasConcept C27081682 @default.
- W2600770137 hasConcept C2776705615 @default.
- W2600770137 hasConcept C2779490328 @default.
- W2600770137 hasConcept C2780259306 @default.
- W2600770137 hasConcept C526805850 @default.
- W2600770137 hasConcept C71924100 @default.
- W2600770137 hasConceptScore W2600770137C121608353 @default.
- W2600770137 hasConceptScore W2600770137C126322002 @default.
- W2600770137 hasConceptScore W2600770137C142724271 @default.
- W2600770137 hasConceptScore W2600770137C143998085 @default.
- W2600770137 hasConceptScore W2600770137C168563851 @default.
- W2600770137 hasConceptScore W2600770137C204787440 @default.
- W2600770137 hasConceptScore W2600770137C27081682 @default.
- W2600770137 hasConceptScore W2600770137C2776705615 @default.
- W2600770137 hasConceptScore W2600770137C2779490328 @default.
- W2600770137 hasConceptScore W2600770137C2780259306 @default.
- W2600770137 hasConceptScore W2600770137C526805850 @default.
- W2600770137 hasConceptScore W2600770137C71924100 @default.
- W2600770137 hasLocation W26007701371 @default.
- W2600770137 hasOpenAccess W2600770137 @default.
- W2600770137 hasPrimaryLocation W26007701371 @default.
- W2600770137 hasRelatedWork W2026445317 @default.
- W2600770137 hasRelatedWork W2100439220 @default.
- W2600770137 hasRelatedWork W2104759721 @default.
- W2600770137 hasRelatedWork W2111237964 @default.
- W2600770137 hasRelatedWork W2134392974 @default.
- W2600770137 hasRelatedWork W2152362765 @default.
- W2600770137 hasRelatedWork W2155167083 @default.
- W2600770137 hasRelatedWork W2165411051 @default.
- W2600770137 hasRelatedWork W2169338340 @default.
- W2600770137 isParatext "false" @default.
- W2600770137 isRetracted "false" @default.
- W2600770137 magId "2600770137" @default.
- W2600770137 workType "article" @default.